Aurinia Pharmaceuticals Inc. - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Aurinia Pharmaceuticals Inc. on August 22, 2016. The filing serves to report a material change and incorporates a Material Change Report (Exhibit 99.1) by reference into the company's Registration Statement on Form F-10 (File No. 333-206994). The registrant is a foreign private issuer filing under Form 40-F.
Financial Metrics
The provided filing text does not contain specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The filing explicitly references a "Material Change Report dated August 22, 2016" as Exhibit 99.1. However, the text of this summary document does not describe the specific nature of the material change, nor does it provide comparative data against prior periods.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, specific risks, contingencies, or details regarding unusual items. The document functions primarily as a cover sheet to incorporate the referenced exhibit.
Key Facts for Investor Verification
- Verify the specific details of the "Material Change" by reviewing Exhibit 99.1, which is incorporated by reference but not detailed in this text.
- Confirm the status of the Registration Statement on Form F-10 (File No. 333-206994) to which this report is attached.
- Note that no financial performance metrics are disclosed in this specific filing; investors must refer to the company's most recent Form 40-F or other financial reports for quantitative data.